Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pharmacyclics LLC.
University of Chicago
Hoffmann-La Roche
St. Jude Children's Research Hospital
National Institutes of Health Clinical Center (CC)
University of Colorado, Denver
Dartmouth-Hitchcock Medical Center
Hutchmed